|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
The natriuretic peptide (NP) family (including ANP (atrial natriuretic peptide), BNP (brain natriuretic peptide), and CNP (C-type natriuretic peptide)), the NP receptors (NPRA, NPRB, and NPRC), and the related protease convertases (furin, corin, and PCSK6) constitute the NP system and represent relevant protective mechanisms toward the development of hypertension and associated conditions, such as atherosclerosis, stroke, myocardial infarction, heart failure, and renal injury.
|
30781751 |
2019 |
|
Hypertensive disease
|
0.600 |
AlteredExpression
|
group |
BEFREE |
The BNP/NT-proBNP levels were higher in PH patients living in the plain region (45.5%), which were mostly in group 4, than in those living the high-altitude region (P < 0.05).
|
31095884 |
2019 |
|
Hypertensive disease
|
0.600 |
GeneticVariation
|
group |
BEFREE |
For example, GWAS of NT-proBNP levels not only identified variants in the NNPA-NPPB locus but also substantiated data suggesting that natriuretic peptides in itself are associated with a lower risk of hypertension and HF.
|
29912321 |
2018 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
NT-pro BNP-A marker for worsening respiratory status and mortality in infants and young children with pulmonary hypertension.
|
29575641 |
2018 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
We assessed the diagnostic value of circulating NT-pro BNP and CXCR3 ligands (MIG, IP10, Interferon-inducible T-cell alpha chemo-attractant [I-TAC]) in patients with hypertension (≥140/90 mm Hg) associated with subclinical (n = 19) or symptomatic (n = 16) diastolic LV dysfunction on echocardiography and healthy controls.
|
26506526 |
2015 |
|
Hypertensive disease
|
0.600 |
GeneticVariation
|
group |
BEFREE |
There were no significant differences in genotype frequency and distribution of the NPPB gene c.-1298 G/T polymorphism between the hypertension group and the control group (P>0.05); in the control group, the mean PP of individuals with the SNP c.-1298 GG genotype was greater than that of individuals with the GT+TT genotype (P<0.05).
|
24841658 |
2014 |
|
Hypertensive disease
|
0.600 |
Therapeutic
|
group |
CTD_human |
Quercetin inhibits left ventricular hypertrophy in spontaneously hypertensive rats and inhibits angiotensin II-induced H9C2 cells hypertrophy by enhancing PPAR-γ expression and suppressing AP-1 activity.
|
24039778 |
2013 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
CTD_human |
Quercetin inhibits left ventricular hypertrophy in spontaneously hypertensive rats and inhibits angiotensin II-induced H9C2 cells hypertrophy by enhancing PPAR-γ expression and suppressing AP-1 activity.
|
24039778 |
2013 |
|
Hypertensive disease
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Impact of a novel mutation in the 5'-flanking region of natriuretic peptide precursor B gene on the antihypertensive effects of sodium nitroprusside in patients with hypertension.
|
22695938 |
2013 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
Clinical trials have documented the benefits and risks of the use of synthetic ANP (Anaritide) and BNP (Nesiritide) for treating heart failure, renal failure, and hypertension.
|
20433683 |
2011 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
BNP gene delivery also improved fractional shortening and ejection fraction in angiotensin II-mediated hypertension as well as decreased myocardial fibrosis and LV collagen III mRNA levels but had no effect on angiogenesis or Ca(2+)-ATPase expression and phospholamban phosphorylation.
|
21558448 |
2011 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
This makes BNP is a clinically useful diagnostic marker for several pathophysiological conditions, including heart failure, ventricular remodeling and pulmonary hypertension, among others.
|
21296556 |
2011 |
|
Hypertensive disease
|
0.600 |
Therapeutic
|
group |
RGD |
Long-term cardiac pro-B-type natriuretic peptide gene delivery prevents the development of hypertensive heart disease in spontaneously hypertensive rats.
|
21403100 |
2011 |
|
Hypertensive disease
|
0.600 |
Therapeutic
|
group |
CTD_human |
Common genetic variants at the NPPA-NPPB locus found to be associated with circulating natriuretic peptide concentrations contribute to interindividual variation in blood pressure and hypertension.
|
19219041 |
2009 |
|
Hypertensive disease
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Common genetic variants at the NPPA-NPPB locus found to be associated with circulating natriuretic peptide concentrations contribute to interindividual variation in blood pressure and hypertension.
|
19219041 |
2009 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
CTD_human |
Common genetic variants at the NPPA-NPPB locus found to be associated with circulating natriuretic peptide concentrations contribute to interindividual variation in blood pressure and hypertension.
|
19219041 |
2009 |
|
Hypertensive disease
|
0.600 |
AlteredExpression
|
group |
LHGDN |
Obese and nonobese patients with essential hypertension show similar N-terminal proBNP plasma levels.
|
18443568 |
2008 |
|
Hypertensive disease
|
0.600 |
AlteredExpression
|
group |
LHGDN |
Does B-type natriuretic peptide predict the new onset of hypertension?
|
18971552 |
2008 |
|
Hypertensive disease
|
0.600 |
GeneticVariation
|
group |
LHGDN |
A novel variable number of tandem repeat of the natriuretic peptide precursor B gene's 5'-flanking region is associated with essential hypertension among Japanese females.
|
17554401 |
2007 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
LHGDN |
The concentration of atrial and brain natriuretic peptide in patients with idiopathic hypertension.
|
17901852 |
2007 |
|
Hypertensive disease
|
0.600 |
AlteredExpression
|
group |
LHGDN |
Two forms of BNP were measured in normal subjects and patients with essential HTN.
|
16648193 |
2006 |
|
Hypertensive disease
|
0.600 |
AlteredExpression
|
group |
BEFREE |
In this study, we investigated the long-term effects of moxonidine treatment on cardiac natriuretic peptides (ANP and BNP) in Spontaneously Hypertensive Obese Rats (SHROBs), a rat model that resembles human Syndrome X. SHROBs expressing spontaneous hypertension, insulin resistance, and genetic obesity (weight 590 +/- 20 g, at 30 weeks) received moxonidine in chow at 4 mg/kg/day for 15 days.
|
15028594 |
2003 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
RGD |
In this study, the role of transcriptional mechanisms in the regulation of BNP gene expression were studied in angiotensin (Ang) II-induced hypertension by injecting DNA constructs containing the BNP promoter (-2200 to 75 bp of the transcriptional start site) linked to luciferase reporter into rat myocardium.
|
11897768 |
2002 |
|
Hypertensive disease
|
0.600 |
AlteredExpression
|
group |
BEFREE |
These results show that the pressure overload-induced activation of BNP gene expression differs between atrial and ventricular myocytes in the dTGR model of experimental hypertension.
|
10803492 |
1999 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
CTD_human |
Human brain natriuretic peptide reduces blood pressure in normotensive and acute norepinephrine-induced hypertensive rabbits.
|
9194512 |
1997 |